EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance

Kiran Malhotra, Joseph Colcombe iD, Sachi Patil, Daniel Vail, Ravi Parikh iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0335390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Kiran Malhotra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, NYU Grossman School of Medicine, New York, New York, United States of America. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors, Medicaid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Anti-vascular endothelial growth factor medications are a cornerstone in the treatment of many macular diseases in modern ophthalmology. These medications accrue significant economic burdens to individuals and health systems, and recent data on health-system level practice patterns involving agent selection is lacking. We sought to examine utilization of intravitreal anti–VEGF agents from 2017 to 2023 across various payors and diagnoses in the United States in order to analyze trends in usage.

Methods

A retrospective cross-sectional study was performed . Data were obtained from the Epic Cosmos database, comprised of de-identified data from the electronic health record, Epic, of 238 million patients from all 50 states from January 1, 2017 to December 31, 2023. Encounters where a patient received an intravitreal injection in an ophthalmology clinic were categorized by intravitreal medication ordered, visit diagnosis, and primary insurance payor. The overall usage rates of each medication across different diagnoses and primary payor were compared. Total number of injections per year of anti-VEGF medication, the rate per 100000 ophthalmology encounters (OE), and the rate in different retinal conditions and with various insurance providers were the main outcome measures.

Results

From 2017–2023, there were 571,545 anti-VEGF injections administered, with 53.6% aflibercept 2 mg (306,247/571,545; 625.8/000 OE), 34.8% bevacizumab 1.25 mg (198,696/571,545; 414.7/100000 OE), 7.83% ranibizumab 0.3 mg and 0.5 mg (44,803/571,545; 99.2/100000 OE), and 3.43% faricimab 6 mg (19,624/571,545; 32.8/100000 OE). Brolucizumab 6 mg, ranibizumab-eqrn 0.5 mg, ranibizumab-nuna 0.5 mg, and aflibercept 8 mg accounted for 0.05] patients. Medicaid patients had a marginally significant difference in use of bevacizumab (M = 19.9/100000 OE, SD = 7.32) and aflibercept 2 mg (16.1/100000 OE, SD = 7.22) [t(6)]=2.95, p = 0.026].

Conclusions

Aflibercept 2 mg was the most common drug used overall from 2017–2023. Faricimab had the highest absolute and relative increase in utilization from 2022–2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsMedicaidUnited StatesHumansCross-Sectional StudiesRetrospective StudiesIntravitreal InjectionsRanibizumabBevacizumabMedicareRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAntibodies, Monoclonal, Humanized

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsRanibizumabBevacizumabafliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorbrolucizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, NYU Grossman School of Medicine, New York, New York, United States of America.
  • Department of Health Informatics, NYU Langone Health, New York, New York, United States of America.
  • New York Eye and Ear Infirmary, New York, New York, United States of America.
  • Manhattan Retina and Eye Consultants, New York, New York, United States of America.

ORCID-Profile: Joseph Colcombe, Ravi Parikh

Zitieren

APA

Malhotra, K., Colcombe, J., Patil, S., Vail, D., & Parikh, R. (2026). U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance. PLOS One. https://doi.org/10.1371/journal.pone.0335390

Vancouver

Malhotra K, Colcombe J, Patil S, Vail D, Parikh R. U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance. PLOS One. 2026. doi:10.1371/journal.pone.0335390

BibTeX
@article{Malhotra2026,
  author = {Malhotra, Kiran and Colcombe, Joseph and Patil, Sachi and Vail, Daniel and Parikh, Ravi},
  title = {U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: An analysis of medicare, medicaid, and commercial insurance},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0335390}
}
Kostenlos starten →